Abstract
Extracorporeal photopheresis (ECP) was given to 23 patients with steroid-refractory acute GVHD (aGVHD, grade II (n=10), III (n=7) or IV (n=6)). The median duration of ECP was 7 months (1–33) and the median number of ECP cycles in each patient was 10. Twelve patients (52%) had complete responses. Eleven patients (48%) survived and 12 died, 10 of GVHD with or without infections and two of leukaemia relapse. The average grade of GVHD was reduced from 2.8 (on the first day of ECP) to 1.4 (on day +90 from ECP) (P=0.08), and the average dose of i.v. methylprednisolone from 2.17 to 0.2 mg/kg/d (P=0.004). Complete responses were obtained in 70, 42 and 0% of patients, respectively, with grades II, III and IV aGVHD; complete responses in the skin, liver and gut were 66, 27 and 40%. Patients treated within 35 days from onset of aGVHD had higher responses (83 vs 47%; P=0.1). A trend for improved survival was seen in grade III–IV aGVHD treated with ECP as compared to matched controls (38 vs 16%; P 0.08). ECP is a treatment option for patients with steroid refractory aGVHD and should be considered early in the course of the disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ferrara JLM, Deeg HJ . Graft-versus-host-disease. N Engl J Med 1991; 324: 667–674.
Anasetti C, Hansen JA . Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Tranfusion Sci 1994; 15: 221–230.
Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, Locatelli R et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomised trial from the Italian group for Bone Marrow Transplantation. Blood 1998; 92: 2288–2293.
Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald JB et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464–1472.
Van Lint MT, Milone G, Leotta S, Uderzo C, Scimèe R, Dallorso S et al. Treatment of acute graft-versus-hot disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-tymocyte globulin. Blood 2006; 107: 4177–4182.
Martin PJ, Shoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB et al. A retrospective analysis of therapy for acute graft-versus-host-disease: secondary treatment. Blood 1991; 62: 626–631.
Lee SJ, Vogelsang G, Flowers ME . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.
Bacigalupo A, Palandri F . Management of acute graft-versus-host disease (GvHD). Hematol J 2004; 5: 189–196.
Rossetti F, Dall'Amico R, Provetti G, Massina C, Montini G, Dini G et al. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. BMT 1996; 18 (Suppl 2): S175–S181.
Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118–127.
Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). BMT 1999; 23: 881–887.
Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G, Giorgiani G et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001; 41: 1299–1305.
Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. BMT 2003; 31: 459–465.
Rubegni P, Cuccia A, Sbano P, Cevenini G, Carcagni MR, D'Ascenzo G et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol 2005; 130: 271–275.
Kanold J, Paillard C, Halle P, D'Incan M, Bordigoni P, Deméocq F . Extracorporeal photochemotherapy for graft versus host disease in pediatric patients. Transfus Apher Sci 2003; 28: 71–80.
Greinix HT, Volc-Platzer B, Rabitsh W, Gmeinhart B, Guevara-Pineda C, Kalhs P et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.
Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematol 2006; 91: 405–408.
Russel-Jones R . Shedding light on photopheresis. Lancet 2001; 357: 820.
Steinman RM, Turley S, Mellman I, Inaba K . The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191: 411–416.
Albert ML . Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004; 4: 223–231.
Greinix HT, Sociè G, Bacigalupo A, Holler E, Edinger MG, Apperley JF et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Meeting report. 2006; 38: 265–273.
Schwarz T . Regulatory T cells induced by ultraviolet radiation. Int Arch Allergy Immunol 2005; 137: 187–193.
Lamioni A, Parisi F, Isacchi G, Giorda E, Di Cesare S, Landolfo A et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846–850.
Maeda A, Schwarz A, Kernebeck K, Gross N, Aragane Y, Peritt D et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induced antigen-specific regulatory T cells. J Immunol 2005; 174: 5968–5976.
Perrit D . Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood marrow Transplant 2006; 12: 7–12.
Gorgun G, Miller KB, Foss FM . Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002; 100: 941–947.
Suchin KR, Cassin M, Washko R, Nahass G, Berkson M, Stouch B et al. Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. J Am Acad Dermatol 1999; 41: 980–986.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee S et al. National Institute of Health consensus development project on criteria for clinical trias in chronic graft versus host disease: I. Diagnosis and staging working report. Biol Blood Marrow Transplant 2005; 11: 945.
Marshall SR . Technology insight: ECP for the treatment of GvHD- can we offer selective immune control without generalized immunosuppression? Nat Clin Pract 2006; 3: 302–314.
Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N.Engl J Med 1987; 316: 297–303.
Dall'Amico R, Murer L . Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apher Sci 2002; 26: 197–204.
Menkes CJ, Andreu G, Heshmati F, Hilliquin P . Extracorporeal photochemotherapy. Br J Rheumatol 1992; 31: 789–790.
Knobler RM . Extracorporeal photochemotherapy for the treatment of lupus erythematosus: preliminary observations. Semin Immunopathol 1994; 16: 323–325.
Rook AH, Jegasothy BV, Heald P, Nahass GT, Ditre C, Witmer WK et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 1990; 112: 303–305.
Dall'Amico R, Messina C . Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6: 296–304.
Dall'Amico R, Rossetti F, Zulian F, Montini G, Murer L, Andreetta B et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997; 97: 848–854.
Lim H W, Eldelson RL . Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1117–1126.
Perseghin P, Dassi M, Balduzzi A, Rovelli A, Bonanomi S, Uderzo C . Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft vs host disease: comparison between Cobe Spectra version 4.7 and 6.0 (Auto PBSC). J Clin Apher 2002; 17: 65–71.
Garban F, Drillat P, Makowski C, Jacob MC, Richard MJ, Favrot M et al. Extracorporeal chemophototherapy for the treatment of graft versus host disease: hematologic consequences of short term, intensive courses. Haematologica 2005; 1096: 101.
Acknowledgements
This work was partly supported by Associazione Italiana Ricerca contro il Cancro (AIRC) Milano, CARIGE, and Fondazione Ricerca per Trapianto Midollo Osseo, Genova.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perfetti, P., Carlier, P., Strada, P. et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 42, 609–617 (2008). https://doi.org/10.1038/bmt.2008.221
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.221
Keywords
This article is cited by
-
Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD)
Bone Marrow Transplantation (2023)
-
Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance
Bone Marrow Transplantation (2020)
-
Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects
Drugs (2019)
-
Inpatient Management of Mucocutaneous GVHD
Current Dermatology Reports (2019)
-
EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment
Bone Marrow Transplantation (2018)